CLEAR LABELS Act

Richard McCormick

Republican · GA · Representative

Source: Congress.gov · FEC

• Rosa L. DeLauro (D-CT-3)Original· 2026-04-14

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2026-04-14

Source: Congress.gov

Without specific subjects listed, this bill likely addresses labeling requirements for consumer products, though the exact focus is unclear. Based on its referral to both the Ways and Means Committee (which handles taxes and trade) and the Energy and Commerce Committee (which oversees consumer protection and product regulation), it probably aims to establish clearer or more standardized labeling rules that could affect manufacturers, retailers, and shoppers. The bill is still in the early stages and hasn't yet been debated or voted on.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8269 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8269 To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 14, 2026 Mr. McCormick (for himself and Ms. DeLauro) introduced the following bill; which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act'' or the ``CLEAR LABELS Act''. SEC. 2. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION. Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended to read as follows: ``(b)(1) If it is a finished drug product in a package form, unless it bears a label containing-- ``(A) the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information; and ``(B) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count, provided that under this clause reasonable variations shall be permitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary. ``(2) If it is an active pharmaceutical ingredient, unless any accompanying label and certificate of analysis contains the name, place of business, and unique facility identifier of the original manufacturer. ``(3)(A) If it is a finished drug product, unless its labeling contains the name, place of business, and unique facility identifier of-- ``(i) the original manufacturer of each active pharmaceutical ingredient; ``(ii) the original manufacturer of the finished drug product; and ``(iii) the packer or distributor, if any, or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information. ``(B) In the case of a finished drug product for which there are multiple potential different manufacturers of the active pharmaceutical ingredient, the requirements of this subparagraph shall be satisfied if all such manufacturers of active pharmaceutical ingredients for the drug product are identified in the labeling or the searchable electronic portal. ``(4) A manufacturer, packer, or distributor required to furnish information under subparagraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy. ``(5) For purposes of this paragraph, the term `original manufacturer', means the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce. ``(6) The Secretary shall issue regulations to implement subparagraphs (2) and (3) and may provide for reasonable variations in the implementation of, or an alternative placement for, the labeling requirements under such subparagraphs, including by electronic means. Such regulations shall take effect on a date determined by the Secretary and not earlier than 1 year after the…

date of publication of the final regulations, and shall apply with respect to drugs manufactured on or after the effective date of such regulations.''. SEC. 3. EXEMPTION FROM CUSTOMS COUNTRY OF ORIGIN MARKING REQUIREMENT. Section 304 of the Tariff Act of 1930 (19 U.S.C. 1304) is amended by adding at the end the following: ``(m) Marking of Certain Finished Drug Products.--The marking requirements of subsections (a) and (b) shall not apply to articles that are finished drug products and are marked in accordance with the requirements of section 502(b)(3)(A) of the Federal Food, Drug, and Cosmetic Act.''. <all>

• HR9755To establishes a new position of Senior Biotechnology Official within the Department of State to enhance United States leadership in global biotechnology challenges by leading United States efforts in biotechnology diplomacy, security, and innovation, and for other purposes.
  Referred to Committee · 2026-07-16
• HR8938Biotechnology Workforce Alignment Act of 2026
  Referred to Committee · 2026-05-20
• HR8580Forestry Protection Act of 2026
  Referred to Committee · 2026-04-29
• HR8455Make DC Square Again Act
  Referred to Committee · 2026-04-22